Q-omics provides the consensus-scored EPHA7 profile across patient tissues and cancer cell-line models. EPHA7 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, EPHA7 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, EPHA7 RNA expression shows 14,708 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRP, and KICH as cancer lineages where EPHA7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EPHA7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EPHA7 survival associations across molecular data types. EPHA7 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (10) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EPHA7 RNA expression–survival associations across cancer types. High EPHA7 expression shows unfavorable associations in ACC, UVM and KICH, but favorable associations in KIRP, KIRC and LUSC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for EPHA7 RNA expression.
This table summarizes EPHA7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for EPHA7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EPHA7 shows lower tumor expression in KICH, COAD, BLCA, THCA, LIHC and BRCA. The KICH box plot shows higher EPHA7 RNA expression in normal versus tumor tissue (log2 FC = −3.248, t-test p < 0.001).
This table shows molecular features associated with EPHA7 in patient tissues and cancer cell lines. In patient samples, EPHA7 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, EPHA7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
